Puma Biotechnology Inc (NYSE:PBYI) Stock Rating Reaffirmed by J P Morgan Chase & Co

Puma Biotechnology Inc (NYSE:PBYI)‘s stock had its “buy” rating restated by equities researchers at J P Morgan Chase & Co in a research report issued on Tuesday, August 1st.

Several other brokerages also recently issued reports on PBYI. BidaskClub upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 31st. Bank of America Corporation restated a “buy” rating and set a $117.00 price objective (up from $100.00) on shares of Puma Biotechnology in a research report on Friday, July 21st. Cowen and Company restated an “outperform” rating and set a $120.00 price objective (up from $91.00) on shares of Puma Biotechnology in a research report on Saturday, July 22nd. Leerink Swann reaffirmed an “outperform” rating and set a $125.00 target price (up from $115.00) on shares of Puma Biotechnology in a report on Wednesday, July 19th. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $105.00 target price on shares of Puma Biotechnology in a report on Friday, June 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $109.56.

Puma Biotechnology (PBYI) opened at 79.75 on Tuesday. The stock has a 50 day moving average price of $87.66 and a 200-day moving average price of $58.07. The company’s market capitalization is $2.97 billion. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $98.85.

Puma Biotechnology (NYSE:PBYI) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by $0.78. Equities analysts predict that Puma Biotechnology will post ($8.62) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Puma Biotechnology Inc (NYSE:PBYI) Stock Rating Reaffirmed by J P Morgan Chase & Co” was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/j-p-morgan-chase-co-reiterates-buy-rating-for-puma-biotechnology-inc-nysepbyi-updated-updated.html.

In other Puma Biotechnology news, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of Puma Biotechnology stock in a transaction on Friday, May 26th. The shares were sold at an average price of $75.38, for a total value of $93,147,066.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Richard Paul Bryce sold 1,998 shares of Puma Biotechnology stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $94.48, for a total transaction of $188,771.04. Following the completion of the sale, the senior vice president now directly owns 27,246 shares of the company’s stock, valued at $2,574,202.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,010,261 shares of company stock worth $159,425,452. 22.70% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Norges Bank acquired a new stake in Puma Biotechnology during the fourth quarter valued at approximately $7,693,000. Emerald Advisers Inc. PA acquired a new stake in Puma Biotechnology during the first quarter valued at approximately $14,110,000. BB Biotech AG increased its stake in Puma Biotechnology by 1.5% in the first quarter. BB Biotech AG now owns 245,616 shares of the biopharmaceutical company’s stock valued at $9,137,000 after buying an additional 3,625 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Puma Biotechnology during the first quarter valued at approximately $7,682,000. Finally, American International Group Inc. increased its stake in Puma Biotechnology by 19.2% in the first quarter. American International Group Inc. now owns 16,931 shares of the biopharmaceutical company’s stock valued at $630,000 after buying an additional 2,733 shares during the last quarter. 80.98% of the stock is owned by hedge funds and other institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply